Akari Therapeutics Plc AKTX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Akari Therapeutics Plc (AKTX) is a healthcare company listed in the US with a market value of about $16M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -438%.
About Akari Therapeutics Plc
Akari Therapeutics Plc is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 7 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$17M | -$20M | -$10M | -$18M | -$17M | -$17M | -$17M |
| Free cash flow | — | — | — | — | — | — | -$13M |
| EPS (diluted) | $-7.44 | $-8.51 | $-4.30 | $-7.63 | $-7.49 | $-7.34 | $-7.24 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -57.5% | -94.6% | — | -1289.1% | -309.9% | -191.6% | -223300.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $25.50, 275% above the current price; targets range from $19.50 to $30.00; the consensus rating is “none”; expected EPS is $-9.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Akari Therapeutics Plc pay a dividend?
Not currently.
Is Akari Therapeutics Plc a good stock to buy?
We do not give buy or sell advice. Akari Therapeutics Plc scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.